UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 19, 2022

Foghorn Therapeutics Inc. (Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-39634 (Commission File Number)

47-5271393 (IRS Employer Identification No.)

500 Technology Square, Ste 700 Cambridge, MA (Address of principal executive offices)

02139 (Zip Code)

(Registrant's telephone number, including area code): (617) 586-3100

Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	FHTX	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \boxtimes

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

Foghorn Therapeutics Inc. (the "Company") is furnishing as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") a presentation, dated May 2022, which the Company intends to use in meetings with or presentations to investors.

The information in this Item 7.01 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

On May 19, 2022, the Company issued a press release announcing that the Food and Drug Administration (the "FDA") has placed the Phase 1 dose escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia ("AML") and myelodysplastic syndrome ("MDS") on a partial clinical hold. The partial clinical hold was initiated by the FDA following the report of a recent death that occurred in a subject with potential differentiation syndrome. Differentiation syndrome is associated with AML/MDS therapeutics that induce differentiation, an effect that is believed to be on-target for the proposed mechanism of action for FHD-286. The FDA has requested a review of the safety database, risk mitigation strategies and a breakdown of clinical activity across dose levels. Until the Company has resolved the partial clinical hold for the AML/MDS study, it is suspending guidance on the timing of the data release for the dose escalation phase of the FHD-286 program.

A copy of the press release is attached to this Current Report as Exhibit 99.2 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

<u>99.1</u>	Investor Presentation dated May 2022
99.2	Press Release issued on May 19, 2022

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

FOGHORN THERAPEUTICS INC.

By:

/s/ Allan Reine Allan Reine, M.D. Chief Financial Officer

Date: May 19, 2022



Targeting the Chromatin Regulatory System

Broadening the Impact of Precision Medicines for Oncology and Other Diseases



May 2022

Forward-Looking Statements



This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "could," "may," "might," "will," "likely," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "expects," "continues," "projects" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning: the potential outcomes from the Collaboration Agreement with Lilly; the initiation, timing, progress and results of our research and development programs and preclinical and clinical trials, including the potential resolution of the partial clinical hold and anticipated timing of release of initial clinical data; our ability to advance product candidates that we may develop and successfully complete preclinical and clinical studies; our ability to leverage our initial programs to develop additional product candidates using our Gene Traffic Control Platform; the impact of the COVID-19 pandemic on our and our collaborators' business operations, including our research and development programs and preclinical studies; developments related to our competitors and our industry; our ability to expand the target populations of our programs and the availability of patients for clinical testing; our ability to obtain regulatory approval for FHD-286, FHD-609 and any future product candidates from the FDA and other regulatory authorities; our ability to identify and enter into future license agreements and collaborations; our ability to continue to rely on our CDMOs and CROs for our manufacturing and research needs; regulatory developments in the United States and foreign countries; our ability to attract and retain key scientific and management personnel; the scope of protection we are able to establish, maintain and enforce for intellectual property rights covering FHD-286 and FHD-609, our future products and our Gene Traffic Control Platform; and our use of proceeds from capital-raising transactions, estimates of our expenses, capital requirements and needs for additional financing. Any forward-looking statements represent the Company's views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements. The Company's business is subject to substantial risks and uncertainties.

FCGHORN

2



Patients impacted by these

cancers

FCGHORN

Based on exome sequencing,


the chromatin regulatory system is implicated in ~50%

of all cancers

3

2030 global oncology

market opportunity



Advancing a Broad Pipeline Across a	Range of Targets and Modalities
Presiding Openlagy / Presetth and Depth	



Program / Target	Modality	Discovery	IND Enabling	Phase 1	Phase 2	Commercial Rights
FHD-286		AML & MDS				FOGHORN
(BRG1/BRM)	Enzyme Inhibitor	Uveal melanoma				FCGHORN
FHD 609 BRD9)	Protein Degrader	Synovial Sarcoma				FOGHORN
	I) Enzyme Inhibitor	BRG1 Mutated Cancers				
Selective BRM	II) Protein Degrader	BRG1 Mutated Cancers				50/50 U.S., Ex-U.S. Royalties
Selective ARID1B	Protein Degrader	ARID1A Mutated Cancers				FOGHORN
Partnered Program (Undisclosed)	Undisclosed					50/50 U.S., Ex-U.S. Royalties
Synthetic Lethal Targets	I) Enzyme Inhibitors					FOGHORN
Multiple)	II) Protein Degraders					FCGHORN
Franscription Factors	I) Transcription Factor Disruptors					FCGHORN
(Multiple)	II) Protein Degraders					FOGHORN
Partnered Program Undisclosed)	Transcription Factor Disruptor					Sector Merck WW Royalties
Three Discovery Programs (Undisclosed)	Undisclosed					FOGHORN LOCO WW Royalties (Opt-in for U.S. Right)

Strategic Collaboration with Loxo Oncology at Lilly Foghorn to Lead Discovery and Research Activities




6

FCGHORN LOXO




The Chromatin Regulatory System

Orchestrates Gene Expression





Breakdowns in the Chromatin Regulatory System can Lead to Disease



Chromatin Regulatory System – Abundance of Targets









BAF Complex and Associated Transcription Factors

FCGHORN



Novel Targets / Dependencies		Tailored Drugging App	Tailored Drugging Approaches	
Chromatin Remodeling Complexes Mutations / Overexpression	-	Enzymatic Inhibitors: Highly selective and allosteric small molecule inhibitors	ATP ADP	
Transcription Factor Mutations / Overexpression		Targeted ProteinDegradation:Bi-functional protein degraders fortargets with no enzymatic activity	ATP ADP	
Mutations that Impinge on the Chromatin Regulatory System		Transcription Factor Disruptors: Disrupt interactions between chromatin remodeling complexes and transcription factors	Potentia druggabl sites	







Heterobifunctional Degrader Platform Foghorn Pursuing >8 Targeted Protein Degraders

Optimal E3 ligase target pairing ٠ **Bioinformatics** . Proteomics Proprietary chromatin remodeling assays • . Protein degradation kinetics Proprietary library of drug-like linkers and E3 ligase binders . • Chemistry to rapidly identify and optimize degraders Structure based optimization of binders . Structural and Computational Approaches to Degrader Design . Ternary complex crystal structures and modeling approaches for degrader optimization Guidelines for both of oral and IV administered degraders . **Optimization of Degrader Drug Properties** . PKPD / efficacy and safety modeling to optimize dosing and scheduling FCGHORN 14

Advancing a Broad Pipeline Across a	Range of Targets and Modalities
Presiding Openlagy / Presetth and Depth	




Program / Target	Modality	Discovery	IND Enabling	Phase 1	Phase 2	Commercial Rights
FHD-286		AML & MDS				FOGHORN
(BRG1/BRM)	Enzyme Inhibitor	Uveal melanoma				FCGHORN
FHD 609 BRD9)	Protein Degrader	Synovial Sarcoma				FOGHORN
	I) Enzyme Inhibitor	BRG1 Mutated Cancers				
Selective BRM	II) Protein Degrader	BRG1 Mutated Cancers				50/50 U.S., Ex-U.S. Royalties
Selective ARID1B	Protein Degrader	ARID1A Mutated Cancers				FOGHORN
Partnered Program (Undisclosed)	Undisclosed					50/50 U.S., Ex-U.S. Royalties
Synthetic Lethal Targets	I) Enzyme Inhibitors					FOGHORN
Multiple)	II) Protein Degraders					FCGHORN
Franscription Factors	I) Transcription Factor Disruptors					FCGHORN
(Multiple)	II) Protein Degraders					FOGHORN
Partnered Program Undisclosed)	Transcription Factor Disruptor					Sector Merck WW Royalties
Three Discovery Programs (Undisclosed)	Undisclosed					FOGHORN LOCO WW Royalties (Opt-in for U.S. Right)





FHD-286: Clinical Entry Point - AML and Uveal Melanoma

FHD-286 is a Potent, Selective, Allosteric, Small Molecule Inhibitor of the BRG1 and BRM subunits of the BAF complex

FHD-286 Targets Abnormal Dependencies on BAF in Cancer








Preclinical FHD-286 Data Shows Broad Efficacy Across AML Patient Derived Samples




Notable Patient ID	Deep Response	Pathology Review	Disease Status
1690AML1	Y	AML	Secondary
1695AML1	Y	AML/MDS	Secondary
1696AML1	Y	AML	Secondary
1701AML1	Y	AML	Secondary
1893AML1	Y	AML	R/R
1899AML1	Y	AML	R/R
1990pAML1	Y	AML	R/R
1991pAML1	Y	AML	de novo
2041AML1	Y	N/A	de novo
2043pAML1	Y	AML	R/R
2059AML1	Y	AML	R/R
1682AML1	~	N/A	N/A
1689AML1	~	AML/MDS	de novo
1684AML1	N	CML	R/R
1924AML1	N	AML/MDS	R/R

FCGHORN


Y = Deep reduction in blast cells ~ = Partial reduction N = No response



20





Dose-Dependent Tumor Growth Inhibition Observed with FHD-286 Treatment in AML CDX Models




22














26


FCGHORN



FHD-609: Clinical Entry Point – Synovial Sarcoma

FHD-609 is a Selective, Potent, Protein Degrader of the BRD9 component of the BAF complex

FHD-609 Targets and Degrades the BRD9 subunit of BAF which is Required for Synovial Sarcoma Cells to Survive




FCGHORN

Target / Approach


Robust *in vivo* Activity Observed in Synovial Sarcoma Model and BRD9 Degradation Associated with FHD-609 Treatment Weekly Dosing of FHD-609 Achieved Sustained BRD9 Degradation





29

Superior Tumor Growth Inhibition of FHD-609 in a Synovial Sarcoma Model as Compared to Ifosfamide and Pazopanib



30

FCGHORN





Synovial Sarcoma FIH Phase 1		
Metastatic Synovial Sarcoma	Synovial sarcoma expansion cohorts	Potential for entry into definitive efficacy trials in synovial sarcoma
 Trial Designs Single patient accelerated titration (n=1) Convert to 3+3 once relevant PK / PD, safety or clinical activity observed Assess safety, PK, clinical activity and biomarkers 	SMARCB-1 deleted tumors and potentially other indications	
 SS18-SSX1, SS18-SSX2 or SS18-SS> 	<4 translocation	
	Initial clinical data i	n 2023




Selective BRM Modulators for BRG1 Mutated Cancers


Enzymatic Inhibitor and Protein Degrader Programs








Enzymatic Selectivity Approaching 200x Achieved








37


FCGHORN



Selective ARID1B Protein Degrader for ARID1A Mutated Cancers

ARID1A: Most Mutated Subunit in BAF Complex – Creates Dependency on ARID1B Selective ARID1B Protein Degrader Overview








Novel Approach to Targeting Transcription Factors


Disrupting Transcription Factor – Chromatin Remodeling Complex Interactions







FCGHORN











Appendix

Proven Leadership Team



Biogen

Officer

......

-pieris- LOMBARD ODIER "迷"

Biogen

Adrian Gottschalk, President & CEO

🖏 Infinity Marina Nelen, Ph.D., VP, Drug Discovery

Michael LaCascia, Chief Legal Officer

Allan Reine, M.D., Chief Financial Officer

Karin Hellsvik, VP Corporate Affairs



Fanny Cavalie, Chief Strategy and Business & Operations Officer Biogen McKinsey &Company

Biogen
 Roche

gsk

Communications

T

Steve Bellon, Ph.D., SVP, Drug Discovery

Carlos Costa, SVP, Human Resources

Ryan Kruger, Ph.D., VP, Biology

Biogen OPARATEK

Danette Daniels, Ph.D., VP, Protein Degradation Platform O Promega

Ben Strain, VP, Investor Relations & Corporate



Scott Innis, VP, Program Leadership Biogen LEERINK



Jacqueline Cinicola, VP Regulatory Affairs 🗻 agios 🛛 🛝



Murphy Hentemann, Ph.D., VP Program Leadership UNOVARTIS AstraZeneca



Chong-Hui Gu, Ph.D., VP, CMC and QA 🗢 ƏQİOS 💮 Bristol-Myers Squibb



Nicola Majchrzak, VP, Clinical Development

Kevin Wilson, VP, Chemistry Sblueprint.

Industry Leading Board of Directors and Advisors



Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS

CAMBRIDGE, Mass. -- (GLOBE NEWSWIRE) -- May 19, 2022 -- Foghorn[®] Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced the Food and Drug Administration (FDA) has placed the Phase 1 dose escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) on a partial clinical hold. The partial clinical hold was initiated by the FDA following the report of a recent death that occurred in a subject with potential differentiation syndrome. Differentiation syndrome is associated with AML/MDS therapeutics that induce differentiation, an effect that is believed to be on-target for the proposed mechanism of action for FHD-286. The FDA has requested a review of the safety database, risk mitigation strategies and a breakdown of clinical activity across dose levels.

Patients currently enrolled in the dose escalation Phase 1 study of FHD-286 in AML/MDS and benefitting from treatment may continue to receive treatment, although no new patients can be enrolled until the partial clinical hold is resolved. The partial clinical hold does not apply to the FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma (mUM), with enrollment in that study continuing per protocol.

"Patient safety remains our top priority. We appreciate the dialogue with the FDA and will work diligently with the Agency to resolve the partial clinical hold in AML/MDS as soon as possible," said Foghorn CEO Adrian Gottschalk.

Until Foghorn has resolved the partial clinical hold for the AML/MDS study, the Company is suspending guidance on the timing of the data release for the dose escalation phase of the FHD-286 program.

About FHD-286

FHD-286 is a highly potent. selective. allosteric and orally available. small-molecule. enzymatic inhibitor of BRG1 and BRM. two highly similar proteins that are the ATPases. or the catalytic engines across all forms of the BAF complex, one of the key regulators of the chromatin regulatory system. In preclinical studies, FHD-286 has shown anti-tumor activity across a broad range of malignancies including both hematologic and solid tumors. To learn more about these studies please visit ClinicalTrials.gov. (Link here for metastatic uveal melanoma and here for AML and MDS).

About AML

Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and the most common type of acute leukemia in adults. AML is a diverse disease associated with multiple genetic mutations. It is diagnosed in about 20,000 people every year in the United States.

About Uveal Melanoma

Uveal (intraocular) melanoma (UM) is a rare eve cancer that forms from cells that make melanin in the iris, ciliary body, and choroid. It is the most common eve cancer in adults. It is diagnosed in about 2.000 adults every vear in the United States and occurs most often in lightly pigmented individuals with a median age of 55 years. However, it can occur in all races and at any age. UM metastasizes in approximately 50% of cases, leading to very poor prognosis.

About Foghorn Therapeutics

Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene

Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology.

Forward-Looking Statements

This press release contains "forward-looking statements." Forward-looking statements include, but are not limited to, statements concerning the Company's clinical programs for FHD-286, including potential resolution of the partial clinical hold and anticipated timing of release of initial clinical data. Forward-looking statements include statements regarding the Company's clinical trials, product candidates and research efforts and other statements identified by words such as "could," "may," "might," "will," "likely," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "expects," "continues," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.

Contact:

Ben Strain, Foghorn Therapeutics Inc. (Media and Investors) <u>bstrain@foghomtx.com</u> Michael Lampe, ScientPR (Media) <u>michael@scientpr.com</u> Hans Vitzhum, LifeSci Advisors (Investors) <u>hans@lifesciadvisors.com</u>